SUBSCRIBE
SUBSCRIBE
News   Policy

Merck & Co., Inc., Cardiome Pharma Corp. Heart Drug Gets Positive EU Review

June 25, 2010 | 
1 min read
LONDON, June 25 (Reuters) - The European Medicines Agency has recommended Merck & Co's (MRK.N) drug Brinavess, or vernakalant, as a treatment for acute atrial fibrillation, or irregular heart beats, the London-based regulator said on Friday.
Regulatory Europe
Merck & Co.
MORE ON THIS TOPIC
Podcast
Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil
July 8, 2026
 · 
1 min read
 · 
Jef Akst
Digital scanning effect of human kidneys glowing in blue, highlighting intricate details with a futuristic design. The image emphasizes respiratory system anatomy and health.
Approvals
Vera moves into growing kidney disease space with FDA’s accelerated IgAN nod
July 7, 2026
 · 
2 min read
 · 
Annalee Armstrong
Creative photo collage geometry figures scales platform weight hands body fragments pointing finger stability spheres measure.
FDA
Despite chaos and churn, FDA decisions hold mostly steady in H1 2026
July 6, 2026
 · 
8 min read
 · 
Tristan Manalac
Editorial
Biotech’s China problem: An issue of national security or economic value for the US?
July 2, 2026
 · 
6 min read
 · 
Jef Akst